NextCure Shares Surge on Positive Data for Bone Treatment

Dow Jones

Jul 26

By Nicholas G. Miller

Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease.

The stock was up 16% to $6.09 on Friday. It is down 34% so far this year.

The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease.

The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

July 25, 2025 12:14 ET (16:14 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2554879957"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554879957\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554879957?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-26 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554879957","market":"us","top_or_hot":-1,"title":"NextCure Shares Surge on Positive Data for Bone Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n</p>\n<p>\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n</p>\n<p>\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n</p>\n<p>\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NextCure Shares Surge on Positive Data for Bone Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNextCure Shares Surge on Positive Data for Bone Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-26 00:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n</p>\n<p>\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n</p>\n<p>\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n</p>\n<p>\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2554879957","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554879957","pubTimestamp":1753460040,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease.The stock was up 16% to $6.09 on Friday. It is down 34% so far this year.The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease.The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NXTC":"Nextcure Inc."},"translate_title":"NextCure股价因骨骼治疗的积极数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXTC":0.9},"content_text":"By Nicholas G. Miller\n\n\n \n\n\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n\n\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n\n\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n\n\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 25, 2025 12:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}